COCHLEAR LIMITED (COH)



Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today » it's FREE! Already a member? Login now!


General Information
Company Name: Cochlear Limited
Stock Code: COH
Website: www.cochlear.com.au
GICS Sub-Industry: Health Care Equipment
Market Cap ($M): 4,050
Equiv. Shares (M): 57

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
 $ 71.000 $ 70.250 $ 71.850 $ 70.180 $ 70.480 237,792 $ 0.520  0.738 %

Current Broker Consensus Recommendation more
Recommendation: Sell
Recommendation Date: 29th Apr 2013
12 Month Target Price (average): $62.323
Brokers Surveyed: 8

Company Overview

Business Description:
Cochlear Limited (COH) is a manufacturer and distributor of cochlear implantable devices for the hearing impaired. With direct operations in more than 20 countries, COH distributes its products in Americas, Asia Pacific, and Europe, Middle East and Africa. COH offers three main products namely: Cochlear Nucleus; Cochlear Baha; and Cochlear Hybrid.

Strategy Analysis:
COH strategy is to maintain its market position as the clear leader in implantable hearing technology. COH has a reputation of delivering the most reliable and safest implantable device provides strong brand awareness with hearing specialists. Management will build on this credibility and its international distribution base to develop product awareness about the Baha device to the larger hearing impaired market. Less than 10% of the profoundly deaf have an implantable hearing device, management expect they can exploit the immaturity of the global market. COH is investing in research to redesign devices to enable manufacturing scale-up from a cottage industry to a production line. Management is also building the infrastructure to handle more revenue by investing in marketing and sales resources. Cochlear reported NPAT of $77.67m for the half-year ended 31 December 2012. Revenues from ordinary activities were $391.7m, up 1% from the same period last year. Sales, excluding FX contracts, were $368.2m, up 5%. In constant currency (that is restating H1 F12 at H1 F13 FX rates), H1 F13 sales were up 9%. Diluted EPS was 136.1 cents compared to (35.8) cents last year. Net operating cash flow was $28.52m compared to $67.37m last year. The interim dividend declared was 125 cents compared with 120 cents last year. Net debt was $72.5m at 31 December 2012. At 31 December, the unused portion of the facility was $60.3m (June 2012, $128.0m).


Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2014  F 183.9 314.9 20.6 22.5 249.0 3.5 50.0
2013  F 152.4 261.0 -6.4 27.2 215.0 3.0 50.0
2012  A 158.1 278.9 -11.7 22.0 245.0 4.0 18.0
Source: Morningstar analyst estimates.

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F
Cochlear (COH) $4,020 M -0.0995 0.0014 0.1184 25.3671 25.3316 22.6507 0.0348 0.0359 0.0363
ResMed (RMD) $7,812 M 0.2200 0.2673 0.1489 29.6866 23.4251 20.3899 0.0000 0.0140 0.0174

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
COH 0.98 25.5 10.50 4.38 5.74
Market 0.83 14.9 1.29 1.81 1.77
Sector 0.72 18.4 2.71 1.55 1.87

Directors
Name Position Start Date
Dr Christopher Graham Roberts Chief Executive Officer,President 01 February 2004
Mr Rick Holliday-Smith Non-Executive Chairman 01 March 2005
Professor Edward Byrne Non-Executive Director 25 June 2002
Mr Andrew Leslie Denver Non-Executive Director 01 February 2007
Yasmin Allen Non-Executive Director 02 August 2010
Mr Paul Ronald Bell Non-Executive Director 01 August 2005
Mr Donal O'Dwyer Non-Executive Director 01 August 2005

Management
Name Position
Neville Mitchell Chief Finance Officer,Company Secretary
David Morris Chief Strategy Officer
Chris Smith President, Americas Region
Mark Salmon President, Asia Pacific Region
Richard Brook President, European Region
Jim Patrick Senior Vice President, Chief Scientist
Jan Janssen Senior Vice President, Design and Development
Michael Kavanagh Senior Vice President, Global Marketing
Bronwyn Evans Senior Vice President, Global Quality, Clinical and Regulatory
Anne-Marie Leslie Senior Vice President, Human Resources
Dig Howitt Senior Vice President, Manufacturing and Logistics

Substantial Shareholders
Holding Name
2,861,083 (5.03%) Harding Loevner LP
3,624,910 (6.37%) Capital Group Companies Inc
4,501,094 (7.91%) Baillie Gifford & Co
4,344,149 (7.63%) Wilson HTM Ltd

Calendar of Events
Date Event
11 March 2014 Report (Interim)
04 February 2014 Report (Interim)
12 September 2013 Report (Annual)
06 August 2013 Report (Prelim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.

Advertisement

Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Trading Forex

An educational booklet with information on becoming a successful trader, including essentials you need to learn and the skills you need to develop.

More details...

News

Plummeting dollar, budget steal limelight

The Age 18/05/2013 | The sharemarket lost ground this week, slipping 0.6 per cent, but the dollar stole the headlines after dropping like an anvil.

Break-up could breathe new life into News

The Age 18/05/2013 | Analysts say the split into two divisions may lead to a re-rating of the embattled publishing business, writes Colin Kruger.

Wesfarmers shares fall short of their Target

The Age 18/05/2013 | Wesfarmers shares suffered their biggest fall in almost two years after sharply lowering Target's earnings forecast.

China the new competitor in Australia's online sales

The Age 18/05/2013 | As Australia's major retailers increase their online sales channels, pouring millions into their websites, they could face new competition from China's booming e-commerce industry.

China roars along e-tailing superhighway

The Age 18/05/2013 | Mass consumption is coming of age in the internet era, write Richard Cooper and Richard Dobbs.

Delayed return to surplus no worry - what causes it is

The Age 18/05/2013 | Most of those who take a political approach to the budget assume that if it's in deficit, the way you get it back to surplus is to cut government spending or, if you're a really bad person, increase taxes. They forget it's the budget itself that's supposed to do the heavy lifting.

More...


Sponsored Links

Feedback Form